Damaj M I
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Box 980613, Richmond, VA 23298-0613, USA.
J Pharmacol Exp Ther. 2007 Jan;320(1):244-9. doi: 10.1124/jpet.106.111336. Epub 2006 Oct 13.
Recent studies have implicated the involvement of Ca2+-dependent mechanisms, in particular, calcium/calmodulin-protein kinase II in nicotine-induced antinociception using the tail-flick test. The spinal cord was suggested as a possible site of this involvement. The present study was undertaken to investigate the hypothesis that the beta2 nicotinic receptor subunit plays a central role in nicotine-induced spinal antinociception via calcium/calmodulin-dependent calmodulin protein kinase II activation. The antinociceptive effects of i.t. nicotine in the tail-flick test did not significantly differ in wild-type and alpha7 knockout (KO) animals but were lost in beta2 knockout mice. When calcium/calmodulin-dependent calmodulin protein kinase II activity in the lumbar spinal cord after acute i.t. administration of nicotine was investigated in wild-type and beta2 and alpha7 knockout mice, the increase in calcium/calmodulin-dependent calmodulin protein kinase II activity was not significant reduced in alpha7 KO mice but was eliminated in the beta2 KO mice. In addition, L-type calcium channel blockers nimodipine and verapamil but not the N-methyl-D-aspartate antagonist MK-801 (dizocilpine maleate) blocked the increase in the kinase activity induced by nicotine. Taken together, these results are consistent with the hypothesis that increases in intracellular calcium result in activation of calcium-mediated second messengers in the spinal cord that play an important role in nicotine-induced antinociception as measured in the tail-flick test. Furthermore, our findings indicate that nicotinic stimulation of beta2-containing acetylcholine nicotinic receptors in the spinal cord can activate calcium/calmodulin-dependent calmodulin protein kinase II and produce nicotinic analgesia, which may require L-type calcium voltage and gated channels but not the intervention of glutamatergic transmission.
最近的研究表明,钙依赖机制参与其中,特别是钙/钙调蛋白 - 蛋白激酶II在尼古丁诱导的镇痛作用中的参与,这是通过甩尾试验得出的结论。脊髓被认为是这一参与过程的可能部位。本研究旨在探讨β2烟碱受体亚基在尼古丁诱导的脊髓镇痛中通过钙/钙调蛋白依赖性钙调蛋白蛋白激酶II激活发挥核心作用这一假说。在甩尾试验中,鞘内注射尼古丁对野生型和α7基因敲除(KO)动物的镇痛作用没有显著差异,但在β2基因敲除小鼠中则消失。当在野生型、β2和α7基因敲除小鼠中研究急性鞘内注射尼古丁后腰段脊髓中钙/钙调蛋白依赖性钙调蛋白蛋白激酶II的活性时,α7基因敲除小鼠中钙/钙调蛋白依赖性钙调蛋白激酶II活性的增加没有显著降低,但在β2基因敲除小鼠中则被消除。此外,L型钙通道阻滞剂尼莫地平和维拉帕米可阻断尼古丁诱导的激酶活性增加,而N - 甲基 - D - 天冬氨酸拮抗剂MK - 801(马来酸氯氮平)则不能。综上所述,这些结果与以下假说一致:细胞内钙的增加导致脊髓中钙介导的第二信使激活,这些第二信使在甩尾试验中测量的尼古丁诱导的镇痛中起重要作用。此外,我们的研究结果表明,脊髓中含β2的乙酰胆碱烟碱受体的烟碱刺激可激活钙/钙调蛋白依赖性钙调蛋白激酶II并产生烟碱镇痛作用,这可能需要L型钙电压门控通道,但不需要谷氨酸能传递的干预。